New or enlarging lesions outside of clinical attacks are rare and far less frequent in MOGAD patients than in multiple sclerosis patients.
Whereas subclinical MRI lesions are often encountered in multiple sclerosis (MS) patients, their frequency in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) or aquaporin-4 positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) has been under debate.
Investigators have now conducted a retrospective study to identify the frequency of new or enlarging T2-hyperintense or enhancing lesions outside of clinical attacks in 105 MOGAD patients (median age, 31 years; 60% female) and to compare the relative frequency of such lesions in MOGAD patients versus MS or AQP4+NMOSD patients. The researchers evaluated 373 paired baseline and follow-up MRI scans of the MOGAD patients and compared results among subgroup…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)